Successful Use of Cefepime-Zidebactam (WCK 5222) as a Salvage Therapy for the Treatment of Disseminated Extensively Drug-Resistant New Delhi Metallo-ß-Lactamase-Producing Pseudomonas aeruginosa Infection in an Adult Patient with Acute T-Cell Leukemia.
Antimicrob Agents Chemother
; : e0050023, 2023 06 14.
Article
in En
| MEDLINE
| ID: mdl-37314343
ABSTRACT
With limited and often toxic treatment options, carbapenem-resistant Gram-negative infections are associated with significant mortality. Cefepime-zidebactam is a promising antibiotic option undergoing a phase 3 trial that has activity against diverse antibiotic-resistant mechanisms in Gram-negative pathogens due to its ß-lactam enhancer mechanism, mediating multiple PBP binding. We report a case of disseminated infection caused by a New Delhi metallo-ß-lactamase-producing, extensively drug-resistant Pseudomonas aeruginosa isolate in a patient with acute T-cell leukemia, successfully managed with cefepime-zidebactam as a salvage therapy.
Key words
Full text:
1
Database:
MEDLINE
Therapeutic Methods and Therapies TCIM:
Plantas_medicinales
Main subject:
Pseudomonas Infections
/
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
Language:
En
Journal:
Antimicrob Agents Chemother
Year:
2023
Type:
Article
Affiliation country:
India